Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities

Area of Science:

• Genomics
• Cancer Biology
• Molecular Oncology

Background:

• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer, but their specific functions in driving cancer hallmarks are not fully understood.
• KRAS-mutant non-small cell lung cancer (NSCLC) presents a significant therapeutic challenge, with limited understanding of the lncRNAs contributing to its progression.

Purpose of the Study:

• To systematically identify and functionally characterize long noncoding RNAs (lncRNAs) that promote oncogenesis in KRAS-mutant non-small cell lung cancer (NSCLC).
• To prioritize lncRNAs with potential as therapeutic targets by assessing their roles in cancer hallmarks like proliferation, chemoresistance, and migration.

Main Methods:

• A pooled CRISPR deletion screen was performed on 831 lncRNAs in KRAS-mutant NSCLC cells to assess their impact on proliferation, chemoresistance, and migration.
• Integrative analysis of screening data was used to identify high-confidence oncogenic lncRNAs.
• Antisense oligonucleotide (ASO) screening was employed to validate the function of top candidate lncRNAs.
• Molecular phenotyping was conducted to elucidate the distinct transcriptional networks controlled by validated lncRNAs.

Main Results:

• The study identified 80 high-confidence oncogenic lncRNAs active in NSCLC, frequently amplified and overexpressed in tumors.
• Two lncRNAs, Cancer Hallmarks in Lung LncRNA 1 (CHiLL1) and GCAWKR, were shortlisted and demonstrated consistent suppression of cancer hallmarks upon knockdown in 2D and 3D tumor models.
• Functional characterization revealed that CHiLL1 and GCAWKR regulate distinct transcriptional networks to control cellular phenotypes.

Conclusions:

• This research uncovers a comprehensive landscape of functional lncRNAs in NSCLC, highlighting their critical roles in driving cancer progression.
• The identified oncogenic lncRNAs, particularly CHiLL1 and GCAWKR, represent potential therapeutic vulnerabilities and novel targets for NSCLC treatment.
• The study demonstrates the power of pooled CRISPR screening and integrative analysis for prioritizing disease-relevant lncRNAs.